271 related articles for article (PubMed ID: 24938757)
21. Clinical research of the value of high-risk CTV setting on intensity-modulated radiotherapy for stage IIB-IVA cervical cancer.
Jiang Y; Wang J; Jiang P; Wang X; Zhang L; Zhang Y
BMC Cancer; 2023 May; 23(1):481. PubMed ID: 37245053
[TBL] [Abstract][Full Text] [Related]
22. Computed tomography-based three-dimensional dosimetry of intracavitary brachytherapy for cervical cancer.
Wadasaki K; Monzen Y; Kurose T; Okazaki H; Mito M
Jpn J Radiol; 2010 Dec; 28(10):740-5. PubMed ID: 21191739
[TBL] [Abstract][Full Text] [Related]
23. Feasibility study of toxicity outcomes using GEC-ESTRO contouring guidelines on CT based instead of MRI-based planning in locally advanced cervical cancer patients.
Koh V; Choo BA; Lee KM; Tan TH; Low JH; Ng SY; Ilancheran A; Shen L; Tang J
Brachytherapy; 2017; 16(1):126-132. PubMed ID: 27816539
[TBL] [Abstract][Full Text] [Related]
24. Dose-volume parameters and clinical outcome of CT-guided free-hand high-dose-rate interstitial brachytherapy for cervical cancer.
Wang Y; Ye WJ; Du LH; Li AJ; Ren YF; Cao XP
Chin J Cancer; 2012 Dec; 31(12):598-604. PubMed ID: 22640625
[TBL] [Abstract][Full Text] [Related]
25. Clinical outcomes of conventional HDR intracavitary brachytherapy combined with complementary applicator-guided intensity modulated radiotherapy boost in patients with bulky cervical tumour.
Lu S; Wang S; Kim RY; Zhang J; Wang X; Wang W; Zhu G; Zhou J; Tan Y; Tan M; Li M; Yin G; Li J; Feng M; Lang J
BJOG; 2023 Jan; 130(2):231-237. PubMed ID: 36330947
[TBL] [Abstract][Full Text] [Related]
26. Dose-volume histogram analysis of composite EQD2 dose distributions using the central shielding technique in cervical cancer radiotherapy.
Tamaki T; Noda SE; Ohno T; Kumazaki Y; Kato S; Nakano T
Brachytherapy; 2016; 15(5):598-606. PubMed ID: 27475482
[TBL] [Abstract][Full Text] [Related]
27. Rotating-shield brachytherapy for cervical cancer.
Yang W; Kim Y; Wu X; Song Q; Liu Y; Bhatia SK; Sun W; Flynn RT
Phys Med Biol; 2013 Jun; 58(11):3931-41. PubMed ID: 23680601
[TBL] [Abstract][Full Text] [Related]
28. Comparison of computed tomography and magnetic resonance imaging in cervical cancer brachytherapy target and normal tissue contouring.
Eskander RN; Scanderbeg D; Saenz CC; Brown M; Yashar C
Int J Gynecol Cancer; 2010 Jan; 20(1):47-53. PubMed ID: 20130502
[TBL] [Abstract][Full Text] [Related]
29. Dose-effect relationship for local control of cervical cancer by magnetic resonance image-guided brachytherapy.
Dimopoulos JC; Pötter R; Lang S; Fidarova E; Georg P; Dörr W; Kirisits C
Radiother Oncol; 2009 Nov; 93(2):311-5. PubMed ID: 19679365
[TBL] [Abstract][Full Text] [Related]
30. Early clinical outcomes of ultrasound-guided CT-planned high-dose-rate interstitial brachytherapy for primary locally advanced cervical cancer.
Mesko S; Swamy U; Park SJ; Borja L; Wang J; Demanes DJ; Kamrava M
Brachytherapy; 2015; 14(5):626-32. PubMed ID: 26024784
[TBL] [Abstract][Full Text] [Related]
31. Dose-volume histogram parameters and local tumor control in magnetic resonance image-guided cervical cancer brachytherapy.
Dimopoulos JC; Lang S; Kirisits C; Fidarova EF; Berger D; Georg P; Dörr W; Pötter R
Int J Radiat Oncol Biol Phys; 2009 Sep; 75(1):56-63. PubMed ID: 19289267
[TBL] [Abstract][Full Text] [Related]
32. Anatomy-based definition of point A utilizing three-dimensional volumetric imaging approach for high-dose-rate (HDR) intracavitary brachytherapy dose prescription when treating cervical cancer using limited resources.
Goyal MK; Rai DV; Kehwar TS; Manjhi J; Heintz BH; Shide KL; Barker JL
J Appl Clin Med Phys; 2016 Jul; 17(6):69-77. PubMed ID: 27929482
[TBL] [Abstract][Full Text] [Related]
33. Concurrent chemoradiotherapy using high-dose-rate intracavitary brachytherapy for uterine cervical cancer.
Toita T; Moromizato H; Ogawa K; Kakinohana Y; Maehama T; Kanazawa K; Murayama S
Gynecol Oncol; 2005 Mar; 96(3):665-70. PubMed ID: 15721409
[TBL] [Abstract][Full Text] [Related]
34. CT-guided intracavitary radiotherapy for cervical cancer: Comparison of conventional point A plan with clinical target volume-based three-dimensional plan using dose-volume parameters.
Shin KH; Kim TH; Cho JK; Kim JY; Park SY; Park SY; Kim DY; Chie EK; Pyo HR; Cho KH
Int J Radiat Oncol Biol Phys; 2006 Jan; 64(1):197-204. PubMed ID: 16169676
[TBL] [Abstract][Full Text] [Related]
35. Novel use of ViewRay MRI guidance for high-dose-rate brachytherapy in the treatment of cervical cancer.
Ko HC; Huang JY; Miller JR; Das RK; Wallace CR; De Costa AA; Francis DM; Straub MR; Anderson BM; Bradley KA
Brachytherapy; 2018; 17(4):680-688. PubMed ID: 29773331
[TBL] [Abstract][Full Text] [Related]
36. Clinical outcome and dosimetric parameters of chemo-radiation including MRI guided adaptive brachytherapy with tandem-ovoid applicators for cervical cancer patients: a single institution experience.
Nomden CN; de Leeuw AA; Roesink JM; Tersteeg RJ; Moerland MA; Witteveen PO; Schreuder HW; van Dorst EB; Jürgenliemk-Schulz IM
Radiother Oncol; 2013 Apr; 107(1):69-74. PubMed ID: 23639580
[TBL] [Abstract][Full Text] [Related]
37. Implications for dosimetric changes when introducing MR-guided brachytherapy for small volume cervix cancer: a comparison of CT and MR-based treatments in a single centre.
Dempsey C; Govindarajulu G; Sridharan S; Capp A; O'Brien P
Australas Phys Eng Sci Med; 2014 Dec; 37(4):705-12. PubMed ID: 25344886
[TBL] [Abstract][Full Text] [Related]
38. Assessing cumulative dose distributions in combined radiotherapy for cervical cancer using deformable image registration with pre-imaging preparations.
Abe T; Tamaki T; Makino S; Ebara T; Hirai R; Miyaura K; Kumazaki Y; Ohno T; Shikama N; Nakano T; Kato S
Radiat Oncol; 2014 Dec; 9():293. PubMed ID: 25526986
[TBL] [Abstract][Full Text] [Related]
39. Feasibility and acute toxicity of Concurrent Chemoradiotherapy (CCRT) with high-dose rate intracavitary brachytherapy (HDR-ICBT) and 40-mg/m2 weekly cisplatin for Japanese patients with cervical cancer: results of a Multi-Institutional Phase 2 Study (JGOG1066).
Toita T; Kitagawa R; Hamano T; Umayahara K; Hirashima Y; Aoki Y; Oguchi M; Mikami M; Takizawa K;
Int J Gynecol Cancer; 2012 Oct; 22(8):1420-6. PubMed ID: 22932262
[TBL] [Abstract][Full Text] [Related]
40. 45 or 50 Gy, Which is the Optimal Radiotherapy Pelvic Dose in Locally Advanced Cervical Cancer in the Perspective of Reaching Magnetic Resonance Image-guided Adaptive Brachytherapy Planning Aims?
Mazeron R; Petit C; Rivin E; Limkin E; Dumas I; Maroun P; Annede P; Martinetti F; Seisen T; Lefkopoulos D; Chargari C; Haie-Meder C
Clin Oncol (R Coll Radiol); 2016 Mar; 28(3):171-7. PubMed ID: 26547694
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
